A Comparison of the Baseline Metabolic Profiles Between Diabetes Prevention Trial-Type 1 and TrialNet Natural History Study Participants

Overview

Journal Pediatr Diabetes

Publisher Wiley

Specialties Endocrinology
Pediatrics

Date 2010 Jun 5

PMID 20522170

Citations 10

Authors

Jay M Sosenko

Jeffrey Mahon

Lisa Rafkin

John M Lachin

Heidi Krause-Steinrauf

Jeffrey P Krischer

David Cuthbertson

Jerry P Palmer

Clinton Thompson

Carla J Greenbaum

Jay S Skyler

Affiliations

Soon will be listed here.

Abstract

Objective: We assessed whether differing autoantibody screening criteria for type 1 diabetes (T1D) prevention trials result in different baseline metabolic profiles of those who screen positive.

Methods: Diabetes Prevention Trial-Type 1 (DPT-1) participants were screened for islet cell autoantibodies, whereas TrialNet Natural History Study (TNNHS) participants were screened for biochemical autoantibodies. In both studies, those determined to be autoantibody positive underwent baseline oral glucose tolerance tests (OGTTs) in which glucose and C-peptide were measured.

Results: The percentage of those with an OGTT in the diabetic range was higher among the DPT-1 participants (10.0% of 956 vs. 6.4% of 645, p < 0.01). In a logistic regression analysis with adjustments for age and gender, the difference persisted (p < 0.01). Among those in the non-diabetic range (n = 860 for DPT-1 and n = 604 for the TNNHS), glucose levels were similar at all time points, except for higher fasting glucose levels in the TNNHS participants (p < 0.001). There was a higher percentage of impaired fasting glucose (IFG) in the TNNHS participants (10.9 vs. 6.7%, p < 0.01); however, with adjustments for age and gender, there was no longer a significant difference. There was no significant difference in the percentages with impaired glucose tolerance. C-peptide levels were much lower in the DPT-1 cohort at all OGTT time points (p < 0.001 for all).

Discussion: Differing criteria for autoantibody screening can result in marked differences in the baseline metabolic profiles of prospective participants of T1D prevention trials.

Citing Articles

Oral Glucose Tolerance Test Measures of First-phase Insulin Response and Their Predictive Ability for Type 1 Diabetes.

Baidal D, Warnock M, Xu P, Geyer S, Marks J, Moran A J Clin Endocrinol Metab. 2022; 107(8):e3273-e3280.

PMID: 35524749 PMC: 9282258. DOI: 10.1210/clinem/dgac285.

HOMA2-B enhances assessment of type 1 diabetes risk among TrialNet Pathway to Prevention participants.

Felton J, Cuthbertson D, Warnock M, Lohano K, Meah F, Wentworth J Diabetologia. 2021; 65(1):88-100.

PMID: 34642772 PMC: 8752172. DOI: 10.1007/s00125-021-05573-6.

Excess BMI Accelerates Islet Autoimmunity in Older Children and Adolescents.

Ferrara-Cook C, Geyer S, Evans-Molina C, Libman I, Becker D, Gitelman S Diabetes Care. 2020; 43(3):580-587.

PMID: 31937610 PMC: 7035590. DOI: 10.2337/dc19-1167.

β Cell dysfunction exists more than 5 years before type 1 diabetes diagnosis.

Evans-Molina C, Sims E, DiMeglio L, Ismail H, Steck A, Palmer J JCI Insight. 2018; 3(15).

PMID: 30089716 PMC: 6129118. DOI: 10.1172/jci.insight.120877.

Dysglycemia and Index60 as Prediagnostic End Points for Type 1 Diabetes Prevention Trials.

Nathan B, Boulware D, Geyer S, Atkinson M, Colman P, Goland R Diabetes Care. 2017; 40(11):1494-1499.

PMID: 28860125 PMC: 5652585. DOI: 10.2337/dc17-0916.

References

Kulmala P, Savola K, Petersen J, Vahasalo P, Karjalainen J, Lopponen T . Prediction of insulin-dependent diabetes mellitus in siblings of children with diabetes. A population-based study. The Childhood Diabetes in Finland Study Group. J Clin Invest. 1998; 101(2):327-36. PMC: 508571. DOI: 10.1172/JCI119879. View

Skyler J, Krischer J, Wolfsdorf J, Cowie C, Palmer J, Greenbaum C . Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial--Type 1. Diabetes Care. 2005; 28(5):1068-76. DOI: 10.2337/diacare.28.5.1068. View

Sosenko J, Krischer J, Palmer J, Mahon J, Cowie C, Greenbaum C . A risk score for type 1 diabetes derived from autoantibody-positive participants in the diabetes prevention trial-type 1. Diabetes Care. 2007; 31(3):528-33. DOI: 10.2337/dc07-1459. View

Verge C, Gianani R, Kawasaki E, Yu L, Pietropaolo M, Chase H . Number of autoantibodies (against insulin, GAD or ICA512/IA2) rather than particular autoantibody specificities determines risk of type I diabetes. J Autoimmun. 1996; 9(3):379-83. DOI: 10.1006/jaut.1996.0051. View

Christie M, Vohra G, Champagne P, Daneman D, Delovitch T . Distinct antibody specificities to a 64-kD islet cell antigen in type 1 diabetes as revealed by trypsin treatment. J Exp Med. 1990; 172(3):789-94. PMC: 2188533. DOI: 10.1084/jem.172.3.789. View

Payton M, Hawkes C, Christie M . Relationship of the 37,000- and 40,000-M(r) tryptic fragments of islet antigens in insulin-dependent diabetes to the protein tyrosine phosphatase-like molecule IA-2 (ICA512). J Clin Invest. 1995; 96(3):1506-11. PMC: 185775. DOI: 10.1172/JCI118188. View

Gorsuch A, Spencer K, Lister J, McNally J, Dean B, Bottazzo G . Evidence for a long prediabetic period in type I (insulin-dependent) diabetes mellitus. Lancet. 1981; 2(8260-61):1363-5. DOI: 10.1016/s0140-6736(81)92795-1. View

Baekkeskov S, Landin M, Kristensen J, Srikanta S, Bruining G, Mandrup-Poulsen T . Antibodies to a 64,000 Mr human islet cell antigen precede the clinical onset of insulin-dependent diabetes. J Clin Invest. 1987; 79(3):926-34. PMC: 424239. DOI: 10.1172/JCI112903. View

Ma X, Becker D, Arena V, Vicini P, Greenbaum C . The effect of age on insulin sensitivity and insulin secretion in first-degree relatives of type 1 diabetic patients: a population analysis. J Clin Endocrinol Metab. 2009; 94(7):2446-51. PMC: 2708949. DOI: 10.1210/jc.2008-2687. View

10.

Lendrum R, Walker G, Cudworth A, Theophanides C, Pyke D, Bloom A . Islet-cell antibodies in diabetes mellitus. Lancet. 1976; 2(7998):1273-6. DOI: 10.1016/s0140-6736(76)92033-x. View

11.

Wilkin T, Hoskins P, Armitage M, Rodier M, Casey C, Diaz J . Value of insulin autoantibodies as serum markers for insulin-dependent diabetes mellitus. Lancet. 1985; 1(8427):480-1. DOI: 10.1016/s0140-6736(85)92086-0. View

12.

Moran A, Jacobs Jr D, Steinberger J, Steffen L, Pankow J, Hong C . Changes in insulin resistance and cardiovascular risk during adolescence: establishment of differential risk in males and females. Circulation. 2008; 117(18):2361-8. DOI: 10.1161/CIRCULATIONAHA.107.704569. View

13.

Gale E, Bingley P, Emmett C, Collier T . European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes. Lancet. 2004; 363(9413):925-31. DOI: 10.1016/S0140-6736(04)15786-3. View

14.

Bottazzo G, Florin-Christensen A, Doniach D . Islet-cell antibodies in diabetes mellitus with autoimmune polyendocrine deficiencies. Lancet. 1974; 2(7892):1279-83. DOI: 10.1016/s0140-6736(74)90140-8. View

15.

. Effects of insulin in relatives of patients with type 1 diabetes mellitus. N Engl J Med. 2002; 346(22):1685-91. DOI: 10.1056/NEJMoa012350. View

16.

Palmer J, Asplin C, Clemons P, Lyen K, Tatpati O, Raghu P . Insulin antibodies in insulin-dependent diabetics before insulin treatment. Science. 1983; 222(4630):1337-9. DOI: 10.1126/science.6362005. View

17.

Mahon J, Sosenko J, Rafkin-Mervis L, Krause-Steinrauf H, Lachin J, Thompson C . The TrialNet Natural History Study of the Development of Type 1 Diabetes: objectives, design, and initial results. Pediatr Diabetes. 2008; 10(2):97-104. DOI: 10.1111/j.1399-5448.2008.00464.x. View